p.71 抽出テキスト

Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology Society of Serbia, Dragan V. Kovačević; Slovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia: Slovenian Society of Cardiology, Igor Zupan; Spain: Spanish Society of Cardiology, David Calvo; Sweden: Swedish Society of Cardiology, Anna Björkenheim; Switzerland: Swiss Society of Cardiology, Michael Kühne; Tunisia: Tunisian Society of Cardiology and Cardiovascular Surgery, Sana Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan; Ukraine: Ukrainian Association of Cardiology, Oleg S. Sychov; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Andre Ng; and Uzbekistan: Association of Cardiologists of Uzbekistan, Husniddin Kuchkarov. ESC Clinical Practice Guidelines (CPG) Committee: Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands). Andrea Sarkozy* (Belgium) *Contributor either stepped down or was engaged in only a part of the review process.

18 References

1. Alam M, Bandeali SJ, Shahzad SA, Lakkis N. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther 2012;10:283–91. https://doi.org/10. 1586/erc.12.8 2. De With RR, Erküner Ö, Rienstra M, Nguyen BO, Körver FWJ, Linz D, et al. Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace 2020;22:1162–72. https://doi.org/10.1093/europace/euaa123 3. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–74. https://doi.org/10.1001/jama.2019.0693 4. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378: 417–27. https://doi.org/10.1056/NEJMoa1707855 5. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 2021;398:1507–16. https://doi. org/10.1016/S0140-6736(21)01698-6 6. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498–506. https://doi.org/10.1016/S0140-6736(21)01637-8 7. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–9. https://doi.org/ 10.1056/NEJMoa1105575 8. McIntyre WF, Healey JS, Bhatnagar AK, Wang P, Gordon JA, Baranchuk A, et al. Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace 2019;21:1159–66. https://doi.org/10.1093/europace/ euz175 9. Bager JE, Martín A, Carbajosa Dalmau J, Simon A, Merino JL, Ritz B, et al. Vernakalant for cardioversion of recent-onset atrial fibrillation in the emergency department: the SPECTRUM study. Cardiology 2022;147:566–77. https://doi.org/10.1159/000 526831 10. Pluymaekers N, Dudink E, Luermans J, Meeder JG, Lenderink T, Widdershoven J, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med 2019;380: 1499–508. https://doi.org/10.1056/NEJMoa1900353 11. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation 2015;131:1648–55. https://doi.org/10.1161/CIRCULATIONAHA. 114.014058 12. Wang EY, Hulme OL, Khurshid S, Weng LC, Choi SH, Walkey AJ, et al. Initial precipitants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol 2020;13:e007716. https://doi.org/10.1161/CIRCEP.119.007716 13. Corica B, Romiti GF, Basili S, Proietti M. Prevalence of new-onset atrial fibrillation and associated outcomes in patients with sepsis: a systematic review and meta-analysis. J Pers Med 2022;12:547. https://doi.org/10.3390/jpm12040547 14. Bedford JP, Ferrando-Vivas P, Redfern O, Rajappan K, Harrison DA, Watkinson PJ, et al. New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur Heart J Acute Cardiovasc Care 2022;11:620–8. https://doi.org/10.1093/ehjacc/zuac080 15. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634–40. https://doi.org/10. 1001/jama.293.21.2634 16. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305–15. https://doi.org/10.1056/NEJMoa2029980 17. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythmcontrol therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16. https://doi.org/10.1056/NEJMoa2019422 18. Coats AJS, Heymans S, Farmakis D, Anker SD, Backs J, Bauersachs J, et al. Atrial disease and heart failure: the common soil hypothesis proposed by the heart failure association of the European Society of Cardiology. Eur Heart J 2022:43:863–7. https://doi. org/10.1093/eurheartj/ehab834 19. Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace 2023;25:6–27. https:// doi.org/10.1093/europace/euac062 20. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/ APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016;18:1455–90. https://doi.org/10.1093/ europace/euw161 21. Sagris D, Georgiopoulos G, Pateras K, Perlepe K, Korompoki E, Milionis H, et al. Atrial high-rate episode duration thresholds and thromboembolic risk: a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e022487. https://doi.org/10.1161/JAHA. 121.022487 22. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6. https:// doi.org/10.1016/j.hrthm.2012.03.017 23. Miyazawa K, Pastori D, Martin DT, Choucair WK, Halperin JL, Lip GYH. Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices. Europace 2022;24:375–83. https://doi.org/10. 1093/europace/euab186 24. Vitolo M, Imberti JF, Maisano A, Albini A, Bonini N, Valenti AC, et al. Device-detected atrial high rate episodes and the risk of stroke/thromboembolism and atrial fibrillation incidence: a systematic review and meta-analysis. Eur J Intern Med 2021;92:100–6. https://doi.org/10.1016/j.ejim.2021.05.038 25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51. https://doi.org/10.1056/NEJMoa0905561 26. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369: 2093–104. https://doi.org/10.1056/NEJMoa1310907 27. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981–92. https://doi.org/10.1056/NEJMoa1107039 28. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91. https://doi. org/10.1056/NEJMoa1009638 29. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527–39. https://doi.org/10.1161/01.CIR.84.2.527 30. Mannina C, Jin Z, Matsumoto K, Ito K, Biviano A, Elkind MSV, et al. Frequency of cardiac arrhythmias in older adults: findings from the subclinical atrial fibrillation and risk of ischemic stroke (SAFARIS) study. Int J Cardiol 2021;337:64–70. https://doi.org/10.1016/j. ijcard.2021.05.006 31. Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103:1024–30. https://doi.org/10.1136/heartjnl-2016-310406 32. Simantirakis EN, Papakonstantinou PE, Chlouverakis GI, Kanoupakis EM, Mavrakis HE, Kallergis EM, et al. Asymptomatic versus symptomatic episodes in patients with paroxysmal atrial fibrillation via long-term monitoring with implantable loop recorders. Int J Cardiol 2017;231:125–30. https://doi.org/10.1016/j.ijcard.2016.12.025 33. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013;173:149–56. https://doi.org/10.1001/jamainternmed.2013.1561 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026